Key facts
- Laplace Interventional’s last known valuation is $71.2M (Feb 2025).
- It has raised $42.0M across 3 recorded rounds; the latest was Early Stage VC ($21.2M) in Feb 2025.
- Notable investors include gBETA, ShangBay Capital, Mayo Clinic, Engage Venture Partners, Aphelion Capital — 10 tracked in total.
- Laplace Interventional has filed 3 Form Ds with the SEC since 2021, most recently Feb 2025 ($21.2M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Laplace Interventional
Funding rounds
3 roundsAbout Laplace Interventional
Provider of a transcatheter tricuspid valve intended to increase life expectancy. The company's device is a prosthetic valve delivered through a minimally invasive procedure that does not require open-heart surgery, enabling doctors to reduce future complications in patients and improve their quality of life.
- Sector
- Healthcare
- HQ
- Plymouth, MN, United States
- Founded
- 2020
- Employees
- 22
- Website
- laplaceint.com/
- Ownership
- Privately Held (backing)
Laplace Interventional doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Laplace Interventional shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Laplace Interventional in its N-PORT filings yet. We sweep new filings monthly.